Systematic review: Faecal microbiota transplantation in the management of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 6, 2012, Pages 503-516

  Anderson, J L ^a   Edney, R J ^a   Whelan, K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETARSOL; ALPHA TOCOPHERYLQUINONE; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LOPERAMIDE; MACROGOL; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; OMEPRAZOLE; PREDNISONE; PROBIOTIC AGENT; RIFAMPICIN; SALAZOSULFAPYRIDINE; VANCOMYCIN;

BIOLOGICAL THERAPY; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; CROHN DISEASE; ENTERITIS; EVIDENCE BASED PRACTICE; FECAL MICROBIOTA TRANSPLANTATION; FOLLOW UP; HUMAN; INFECTIOUS DIARRHEA; INTESTINE; INTESTINE FLORA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL TRACT;

FECES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; METAGENOME; MICROBIAL INTERACTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION;

EID: 84865494677     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05220.x     Document Type: Review

References (58)

1. Hedin C, Whelan K, Lindsay JO,. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007; 66: 307-15. (Pubitemid 47076227)
2. Nagalingam NA, Lynch SV,. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 968-84.
3. DuPont AW, DuPont HL,. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8: 523-31.
4. Sartor RB,. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-94. (Pubitemid 351173057)
5. Vernia P,. Butyrate in the treatment of ulcerative colitis. Digest Liver Dis 2007; 1 (Suppl. 1): 27-30.
6. Hamer HM, Jonkers DM, Vanhoutvin SA, et al,. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 2010; 29: 738-44.
7. Talley NJ, Abreu MT, Achkar JP, et al,. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106: S2-25.
8. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
9. Bernstein CN, Loftus EV Jr, Ng SC, et al,. Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: 622-9.
10. Lix LM, Graff LA, Walker JR, et al,. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1575-84.
11. Meijer BJ, Dieleman LA,. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011; 45: S139-44.
12. Benjamin JL, Hedin CR, Koutsoumpas A, et al,. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923-9.
13. Gough E, Shaikh H, Manges AR,. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infec Dis 2011; 53: 994-1002.
14. Borody TJ, Khoruts A,. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2011; 9: 88-96.
15. Landy J, Al-Hassi HO, McLaughlin SD, et al,. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34: 409-15.
16. Eiseman B, Silen W, Bascom GS, et al,. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-9.
17. Guo B, Harstall C, Louie T, et al,. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35: 865-75.
18. Sinh P, Barrett TA, Yun L,. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Prac 2011; 2011: 136064.
19. Nguyen GC, Kaplan GG, Harris ML, et al,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50. (Pubitemid 351813903)
20. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, March 2011. Available at: http://www.cochrane-handbook.org.
21. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
22. Aas J, Gessert CE, Bakken JS,. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infec Dis 2003; 36: 580-5. (Pubitemid 36259562)
23. Grehan MJ, Borody TJ, Leis SM, et al,. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44: 551-61.
24. Borody TJ, Wettstein AR, Leis S, et al,. Clostridium difficile complicating inflammatory bowel disease: pre- and post-treatment findings. Gastroenterology 2008; 134: A361-A361.
25. Wettstein A, Borody TJ, Leis SM, et al,. Fecal bacteriotherapy-an effective treatment for relapsing symptomatic clostridium difficile infection. Paris: United European Gastroenterology Federation, 2007.
26. Borody TJ, George L, Andrews P, et al,. Bowel-flora alteration-a potential cure for inflammatory bowel-disease and irritable bowel syndrome. Med J Australia 1989; 150: 604-604.
27. Mellow M, Kanatzar A,. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection-results and follow-up. Am J Gastroenterol 2010; 105: S135-S135.
28. Borody T, Campbell J, Torres M, et al,. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. Am J Gastroenterol 2011; 106: S352-S352.
29. You D, Johnson M, Duplessis C, et al,. Successful use of fecal bacteriotherapy in severe Crohn's colitis and refractory Clostridium difficile infection. Am J Gastroenterol 2011; 106: S315-S315.
30. Borody T, Torres M, Campbell J, et al,. Reversal of inflammatory bowel disease (IBD) with recurrent faecal microbiota transplants (FMT). Am J Gastroenterol 2011; 106: S366.
31. Borody T, Leis S, McGrath K, et al,. Treatment of chronic constipation and colitis using human probiotic infusions. In: Probiotics, Prebiotics and New Foods Conference, Universita Urbaniana, Rome; September 2-4, 2001.
32. Vermeire S, Joossens M, Verbeke K, et al,. Pilot study on the safety and efficacy of faecal microbiota transplantation in refractory crohn's disease. Gastroenterology 2012; 142: S360.
33. Zainah H, Silverman A,. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis 2012; 2012: 810943.
34. Borody TJ, Warren EF, Leis S, et al,. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-7. (Pubitemid 36734332)
35. Bennet JD, Brinkman M,. Treatment of ulcerative-colitis by implantation of normal colonic flora. Lancet 1989; 1: 164-164.
36. Angelberger S, Lichtenberger C, Gratzer C, et al,. Fecal transplantation in patients with moderately to severely chronic active ulcerative colitis (UC). In ECCO Conference Abstracts 2012. p. P374.
37. Watson JB, Habr F, Kelly C,. First reported complication of fecal microbiota transplant: ulcerative colitis flare after FMT for relapsing Clostridium difficile infection. Gastroenterology 2012; 142: S540.
38. Neelakanta A, Moudgal V, Upadhyay N, et al,. Successful treatment of refractory Clostridium difficile infection(CDI) with intestinal microbiotatransplant (IMT) in two patients with inflammatory bowel disease (IBD) and its effects on IBD. Gastroenterology 2012; 142: S395.
39. Parkes GC, Sanderson JD, Whelan K,. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infec Dis 2009; 9: 237-44.
40. Khoruts A, Dicksved J, Jansson JK, et al,. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44: 354-60.
41. Gustafsson A, Berstad A, Lund-Tonnesen S, et al,. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol 1999; 34: 580-6. (Pubitemid 29339211)
42. Gustafsson A, Lund-Tonnesen S, Berstad A, et al,. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998; 33: 721-7. (Pubitemid 28358056)
43. Chang JY, Antonopoulos DA, Kalra A, et al,. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-8. (Pubitemid 351263426)
44. Ng SC, Benjamin JL, McCarthy NE, et al,. Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in crohn's disease. Inflamm Bowel Dis 2011; 17: 2027-37.
45. Sokol H, Pigneur B, Watterlot L, et al,. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-6.
46. Naidoo K, Gordon M, Fagbemi AO, et al,. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; 12: CD007443.
47. Casellas F, Borruel N, Torrejon A, et al,. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007; 25: 1061-7. (Pubitemid 46587689)
48. Manichanh C, Reeder J, Gibert P, et al,. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res 2010; 20: 1411-9.
49. Glauser W,. Risk and rewards of fecal transplants. Can Med Assoc J 2011; 183: 541-2.
50. Kelly C, de Leon L, Kerstetter D, et al,. Barriers to greater utilization of fecal bacteriotherapy for chronic Clostridium difficile infection. Am J Gastroenterol 2010; 105: S135-6.
51. Kahn SA, Gorawara-Bhat R, Rubin DT,. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis 2012; 18: 676-84.
52. Kahn SA, Vachon AI, Marks JA, et al,. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Gastroenterology 2012; 142: S357.
53. Joossens M, Huys G, Cnockaert M, et al,. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631-7.
54. Hedin CR, Stagg AJ, Whelan K, et al,. Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut 2012; 61: 311-8.
55. Ioannidis JP,. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009; 169: 1737-9.
56. Bakken JS, Borody T, Brandt LJ, et al,. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9.
57. Stange EF, Travis SP, Vermeire S, et al,. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23. (Pubitemid 351179487)
58. Van Assche G, Dignass A, Panes J, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.